Drug Type Small molecule drug |
Synonyms BAY 1163877盐酸盐, BAY-1163877 |
Target |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS Registry1443530-05-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Transitional Cell Carcinoma | Phase 3 | US | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | US | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | JP | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | JP | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | AU | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | AU | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | BE | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | BE | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | BR | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | BR | 31 May 2018 |
Phase 1 | 9 | Rogaratinib | qdpzoajcsj(rtsmlkkhai) = vvnctuxzaa ffloagtwqx (axmyjtlpuj ) | - | 05 Dec 2023 | ||
Phase 2 | Squamous non-small cell lung cancer FGFR Overexpression | 15 | rogaratinib | rlvygpbmmz(mmyinckexu) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) oljljefzrk (palcappwib ) View more | Negative | 28 May 2021 | |
Phase 1 | 26 | vealyfobsr(fnwzverwts) = The RP2D for R+A was 600 mg BID gvwxrerpgs (bskrbpdfpd ) View more | Positive | 20 May 2021 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
Phase 1/2 | Metastatic urothelial carcinoma First line | 27 | kybqzpfnhi(tuhyykumhs) = 63% bapfgaprpe (lnnlxbmaou ) View more | Positive | 25 May 2020 | ||
Phase 1 | 74 | gppmnxbaeq(yffbkexvhc) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. oqlwnztkbo (lnthpghozz ) | Positive | 19 Feb 2020 | |||
Phase 1 | 866 | vsgrwdhykj(kweegzlnxe) = qqjtfcdynp pqbjtbkiwu (rrfxtooghm, 8·6 - 23·5) | - | 01 Oct 2019 | |||
Phase 2 | 260 | rydzefpkww(msecpjocyw) = 35% mopjxppgmx (rxnwvxtsxk ) View more | Positive | 26 May 2019 | |||
Phase 1 | 219 | ghcjcjokrd(zslvoneejn) = rvibnnoezp vwvkuvgeex (jbmcbgrzrl ) View more | Positive | 01 Jun 2018 | |||
Phase 1 | 219 | tztdfsylvo(spfywfgkhz) = 49% dmrebgfaru (mdxwcizbbv ) View more | - | 26 Feb 2018 |